Tel Aviv, Israel

Tal Ohayon

This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Flexera Software LLC, Netapp, Inc.. Active years: 2026.

USPTO Granted Patents = 2 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tal Ohayon: Innovator in Resource Availability Prediction

Introduction

Tal Ohayon is a notable inventor based in Tel Aviv, Israel. He has made significant contributions to the field of technology, particularly in the area of resource availability prediction. His innovative approach leverages limited historical data to enhance the efficiency of networked systems.

Latest Patents

Tal Ohayon holds a patent titled "Spare resource availability prediction with limited historical data." This patent describes a system that includes a memory for storing computer executable components and a processor that executes these components. The system features a correlation component that identifies spare resource instances within a networked system and an evaluation component that generates an availability score. This score predicts the availability of resources, allowing for better deployment in networked environments.

Career Highlights

Tal Ohayon is currently employed at Flexera Software LLC, where he continues to develop innovative solutions in resource management. His work focuses on improving the efficiency and reliability of networked systems through advanced predictive technologies.

Collaborations

Tal collaborates with Idan Schwartz, a coworker at Flexera Software LLC. Together, they work on projects that aim to enhance the capabilities of resource management systems.

Conclusion

Tal Ohayon is a pioneering inventor whose work in resource availability prediction is shaping the future of networked systems. His contributions are vital for improving efficiency in technology-driven environments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…